Evidence map›Paper›PMID 41339802›Full record

ArticleBMC cancer2025

Global, regional, and national burdens of bladder cancer attributable to high fasting plasma glucose from 1990 to 2021, with future forecasts to 2050: a systematic analysis for the global burden of disease study 2021.

Kaijian Lan, Yuanfeng Zhang, Yingxun Luo, Ting Hong, Xinyu Liu, Yangcheng Hu, Weiqiang Lin, Xuwei Hong, Yonghai Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kaijian Lan *Department of Urology, Shantou Central Hospital, Shantou, Guangdong, 515031, China.
Yuanfeng Zhang *Department of Urology, Shantou Central Hospital, Shantou, Guangdong, 515031, China.
Yingxun LuoDepartment of Urology, Shantou Central Hospital, Shantou, Guangdong, 515031, China.
Ting HongClinical Medical Research Center, Shantou Central Hospital, Shantou, Guangdong, 515031, China.
Xinyu LiuClinical Medical Research Center, Shantou Central Hospital, Shantou, Guangdong, 515031, China.
Yangcheng HuDepartment of Urology, Shantou Central Hospital, Shantou, Guangdong, 515031, China.
Weiqiang LinDepartment of Urology, Shantou Central Hospital, Shantou, Guangdong, 515031, China.
Xuwei HongDepartment of Urology, Shantou Central Hospital, Shantou, Guangdong, 515031, China. hong_xuwei@sina.cn.
Yonghai ZhangDepartment of Urology, Shantou Central Hospital, Shantou, Guangdong, 515031, China. zhang_yonghai@126.com.

Funding

Guangdong Basic and Applied Basic Research Foundation 2023A1515220184, 2023A1515220213National Natural Science Foundation of China 82372685Research Project of Guangdong Provincial Administration of Traditional Chinese Medicine 20262049Science and Technology Planning Projects of Guangdong Province STKJ202209068
6 · The paper itself

Abstract

backgroundThe aim of this study was to characterize global, regional, and national burden in bladder cancer attributable to high fasting plasma glucose (HFPG) from 1990 to 2021 and future forecasts to 2050.

methodsThe data were sourced from the Global Burden of Disease 2021 study. Deaths and disability-adjusted life years (DALYs) data were analyzed via age-standardized rates. The estimated annual percentage change was computed. Age-period-cohort analysis was employed to estimate the age, period, and cohort effects of bladder cancer attributable to HFPG. Moreover, bayesian age-period-cohort model was utilized to project the burden of bladder cancer attributable to HFPG to 2050.

resultsThe global deaths of bladder cancer attributable to HFPG increased from 6,092 cases in 1990 to 17,562 cases in 2021, while the age-standardized death rate rose from 0.176 per 100,000 people in 1990 to 0.213 per 100,000 people in 2021. The burden of bladder cancer attributable to HFPG rose in all socio-demographic index (SDI) regions. Singapore had lowest increase in age-standardized DALYs rate of bladder cancer attributable to HFPG from 1990 to 2021. The age group with the highest number of deaths was 80-84 age group, regardless of gender, with 805 females and 2,430 males. The burden of bladder cancer attributable to HFPG are generally on the rise from 2021 to 2050.

conclusionsThe growing global burden of bladder cancer attributable to HFPG needs urgent health interventions, especially in high SDI regions.

trial registrationNot applicable.

Indexed as

Blood GlucoseFastingGlobal Burden of DiseaseUrinary Bladder NeoplasmsAdultAgedAged, 80 and overDisability-Adjusted Life YearsFemaleForecastingHumansMaleMiddle AgedBlood GlucoseAge-period-cohortBayesian age-period-cohort modelBladder cancerGlobal burden of diseaseHigh fasting plasma glucose

Identifiers

PMID41339802
PMCPMC12794374

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.